منابع مشابه
Metronomic Chemotherapy for Metastatic Breast Cancer
The present study demonstrates that metronomic docetaxel–capecitabine chemotherapy with daily celecoxib can produce significant anticancer activity, with predictable toxicity. Efficacy fell short of expectations, with outcome measures being similar to those obtained when the study agents are given in conventional dosing. Furthermore, there is mounting evidence to indicate that a low dose of tax...
متن کاملMetronomic chemotherapy for triple negative breast cancer?
Despite the incidence for women older than 70 years being 33%, they are usually excluded from screening schedules and clinical trials. Furthermore, about 15% of breast cancers in older patients are of the triple-negative subtype (TNBC), which is known to be an aggressive histological subtype with very limited treatment options available, and associated with a very poor prognosis [1]. Indeed, th...
متن کاملMetronomic chemotherapy in metastatic breast cancer: impact on VEGF.
BACKGROUND Anticancer chemotherapy is thought to be effective by means of direct cytotoxicity on tumor cells. Alternative mechanisms of efficacy have been ascribed to several common anticancer agents; including cyclophosphamide (CTX) and capecitabine (Cap) when given at lower doses for prolonged period (metronomic chemotherapy) postulating an antiangiogenic activity as well. AIM OF WORK To ev...
متن کاملIllness perception of breast cancer in affected women undergoing chemotherapy
Abstract Background: The aim of this study was to investigate the various aspects of illness perceptions about breast cancer in affected patients. Methods: A cross-sectional study enrolled 140 patients with breast cancer in their chemotherapy period within 14 months. The revised Illness Perception Questionnaire (revised IPQ) was used to assess the disease representations of breast cancer. The ...
متن کاملLow-Dose Metronomic Chemotherapy in Metastatic Breast Cancer: A Retrospective Analysis of 40 Patients
Purpose: Low-dose metronomic chemotherapy is an emergent treatment schedule in which low doses of cytotoxic agents are given orally continuously, with no or short drug-free intervals. In general, it provides better tolerance, especially in patients who have been previously exposed to other oncologic treatments, with a favorable cost-effectiveness profile. It is well known that all these low-dos...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Onkologie
سال: 2016
ISSN: 1802-4475,1803-5345
DOI: 10.36290/xon.2016.035